If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What potential drug-drug interactions does EMGALITY® (galcanezumab-gnlm) have?
Drug interaction studies were not conducted. No pharmacokinetic drug interactions are expected based on the characteristics of Emgality (galcanezumab).
Drug Interactions with Galcanezumab Are Not Known or Expected
Pharmacokinetic Characteristics of Galcanezumab Metabolism
Galcanezumab is an immunoglobulin G (subclass 4) monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous immunoglobulin G.1-4
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780
3Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs - lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1180. https://doi.org/10.3390/pharmaceutics12121180
4Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
5Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. https://doi.org/10.1002/jps.20178
Date of Last Review: October 28, 2024